KOL洞察报告丨神经内分泌肿瘤治疗的现状与挑战10407（英）_9页_1mb

KOL Insights Summary: Neuroendocrine Tumors (NET) in Spain

Core Content

This summary outlines the insights provided by a medical oncologist specializing in Neuroendocrine Tumors (NETs) in Spain. The discussion covers the diagnosis, treatment, and unmet needs in NET management, as well as the role of biomarkers and clinical trials.

Main Points

1. Diagnosis and Prognosis

• In Spain, the incidence of NETs is approximately 4-5 cases per 100,000 population.
• 40% of cases are well-differentiated carcinomas.
• 40% are intermediate or moderately differentiated.
• 20% are poorly differentiated.
• 70% of patients are diagnosed at an early stage, while 30% are diagnosed at advanced or metastatic stages.
• 40% of early-stage patients may develop late-stage disease within five years.

2. Tumor Locations

• 60% of NETs originate from the gastrointestinal tract, with:
  • 20% from the small intestine.
  • 5% from the stomach.
  • 5% from the appendix.
• 25% from the pancreas.
• 20% from the lung or thymus.

3. Treatment Approaches

• Early-stage patients are mainly treated with surgery, as it can lead to a cure.
• Metastatic patients are treated based on somatostatin receptor expression:
  • 70% of patients express the somatostatin receptor and receive somatostatin analogs like octreotide or lanreotide.
  • 30% of patients do not express the receptor and may receive sunitinib, everolimus, or other drugs.
• Second-line treatment includes Lutathera (Lutetium Dotatate), which is approved for second-line use after somatostatin analogs.
• Lutathera is considered the most effective treatment for somatostatin receptor-positive NETs.
• Lutathera is administered every 8 weeks and is available within 2 days of prescription.

4. Clinical Trials and Immunotherapy

• Immunotherapies like axitinib, pembrolizumab, and avelumab are being explored for NET carcinoma, especially in clinical trials.
• These therapies have been approved for kidney cancer and may offer new treatment options for NET patients who progress on standard therapies.
• Pasireotide is not approved for NET carcinoma and is only used for Cushing’s disease or acromegaly.

5. Unmet Needs

• Early diagnosis is a major challenge, as tumors can be 1-2 cm in size and detection is difficult.
• PET imaging and other biomarkers could improve early detection.
• More effective treatments are needed, as current therapies often result in slight responses and long-term management.
• Targeted therapies with better response rates could reduce complications like osteoporosis and improve patient quality of life.

6. Somatostatin Analog Usage

• Lanreotide is preferred over octreotide due to its depot formulation, allowing once-daily administration.
• Branded lanreotide (Somatuline Autogel) is typically used in outpatient settings, while generic versions are used in hospital settings.

7. Future Therapies

• Curium's new lutetium formulation (alpha emitter) may compete with Lutathera if it offers subcutaneous or oral administration or longer dosing intervals.
• RYZ101, PNT2003, and Endolucin Beta are radiopharmaceuticals in development and may be similar to Lutathera in mechanism, but their specificity could affect efficacy.
• Oclaiz, a long-acting octreotide, is expected to compete with existing somatostatin analogs, especially if locally manufactured, which allows better communication with pharmaceutical companies.

Key Information

• Adjuvant treatment is used in only 20% of early-stage patients, typically those with poor prognosis features.
• 100% of patients who relapse locally or at a distant stage receive treatment.
• Progression from first to second line occurs in 100% of metastatic patients, with a 3-year interval between lines.
• Insurance and reimbursement issues are common for immunotherapies and clinical trial drugs, as they are not approved for NETs.
• Bone-related tests like densitometry and bone scintigraphy are routine for NET patients due to the high frequency of bone metastases.

Conclusion

The medical oncologist emphasizes the importance of early diagnosis, targeted therapies, and clinical trials in improving NET treatment outcomes. Despite the challenges, Lutathera remains a key treatment option for second-line therapy, and future developments in radiopharmaceuticals and immunotherapies could significantly impact patient care.